Last updated on June 2019

Phase 1/2 Study Exploring the Safety Tolerability and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies


Brief description of study

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.

Clinical Study Identifier: NCT03126110

Find a site near you

Start Over

Institut Jules Bordet

Brussels, Belgium
6.69miles
  Connect »

CHU Brugmann

Bruxelles, Belgium
9.55miles
  Connect »